11th CONFERENCE OF THE EUROPEAN HIDRADENITIS SUPPURATIVA FOUNDATION

Innovating the HS future.
February 9–11, 2022 | Virtual

www.ehsf2022.com
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>01</strong> WELCOME MESSAGE</td>
<td>03</td>
</tr>
<tr>
<td><strong>02</strong> ABOUT EHSF</td>
<td></td>
</tr>
<tr>
<td>Our history</td>
<td>05</td>
</tr>
<tr>
<td>1st International Hidradenitis Suppurativa Research Symposium</td>
<td>05</td>
</tr>
<tr>
<td>Last HSF, Inc. Board with European Participation</td>
<td>05</td>
</tr>
<tr>
<td>Inauguration of EHSF e.V.</td>
<td>06</td>
</tr>
<tr>
<td>Founding Members</td>
<td>06</td>
</tr>
<tr>
<td>Congresses</td>
<td>07</td>
</tr>
<tr>
<td>Our Goals</td>
<td>07</td>
</tr>
<tr>
<td><strong>03</strong> COMMITTEES</td>
<td></td>
</tr>
<tr>
<td>Organizing Committee</td>
<td>09</td>
</tr>
<tr>
<td>Scientific Committee</td>
<td>10</td>
</tr>
<tr>
<td>Local Organizing Committee</td>
<td>11</td>
</tr>
<tr>
<td><strong>04</strong> FEBRUARY 09, 2022 PROGRAM WED</td>
<td></td>
</tr>
<tr>
<td>Overview</td>
<td>13</td>
</tr>
<tr>
<td>Program</td>
<td>14</td>
</tr>
<tr>
<td><strong>05</strong> FEBRUARY 10, 2022 PROGRAM THU</td>
<td></td>
</tr>
<tr>
<td>Overview Program</td>
<td>15</td>
</tr>
<tr>
<td>Program</td>
<td>16</td>
</tr>
<tr>
<td><strong>06</strong> FEBRUARY 11, 2022 PROGRAM FRI</td>
<td></td>
</tr>
<tr>
<td>Overview Program</td>
<td>23</td>
</tr>
<tr>
<td>Program</td>
<td>24</td>
</tr>
<tr>
<td><strong>07</strong> POSTERS</td>
<td>30</td>
</tr>
<tr>
<td><strong>07</strong> GENERAL INFORMATION</td>
<td>37</td>
</tr>
</tbody>
</table>

Stand: 1 February, 2022
Dear colleagues,

in 2021, the 10th European Hidradenitis Suppurativa Foundation (EHSF) Conference celebrating 15 years of fascinating work became a great success thanks to you and despite the obligatory experiment to hold it as a virtual event. A total of 138 scientific contributions and 688 participants from 52 countries undersigned your trust and sense of being affiliated with a society, which leads the research and clinical activities on hidradenitis suppurativa (HS) around the globe.

After the international thematic conferences in Dessau (2006), San Francisco (2009), Brussels (2014 and 2016), Berlin (2016), Copenhagen (2017), Rotterdam (2018), Wroclaw (2019), Athens (2020) and the 2021 virtual conference, we had planned to organize the 11th EHSF Conference at the wonderful city of Potsdam, Germany. The continuation of the pandemic has obliged us, however, to offer you instead a virtual event. Based on the last year’s experience, we have strictly followed our target to provide a scientific event of even higher level. The motto of this year’s Conference is “Innovating the future” and this undersigns the tremendous ongoing research development on HS from the laboratory bench to the clinic. Moreover, we want to intensify our purpose to encourage international cooperation in the field.

Indeed, we have left the legendary pioneer days long behind us. The dedication of clinicians and scientists on the disease as well as the interest of the pharmaceutic industry for introducing new therapeutic means have increased exponentially. There is no doubt, that HS is a dermatological disease, but the identified comorbid disorders induce the attention of other specialists, too. Nurses start to consider HS as an important part of their duties. Patients contribute actively, since they have been organized in several national self-aid groups. A first compound for medical treatment has been registered with many more just been before registration. In the meantime, the EHSF e. V. has grown up and provides a series of significant contributions in the field through valuable cooperative projects of its members towards the discovery of HS etiopathogenesis, phenotypization, association with comorbid disorders and biomarkers, establishing of robust diagnostic and classification criteria, outcome measure instruments and guidelines for the treatment of the disease.

The 11th EHSF Conference will not only present these huge developments, which facilitate a better understanding of HS and support the needs of medical and psychological care of HS patients but will also target the major developments for the years to come. Parallelly, the EHSF e.V. opens its doors to invite all caring physicians and scientists, independently of their specialization, to participate, since HS requires an interdisciplinary approach. We have constructed a scientific programme of high impact to satisfy the most demanding expectations for up-to-date information on research and clinical data with relevance on HS. The invited speakers and those of you chosen to actively contribute through the evaluation procedure of the submitted works, include international experts thinking outside the box and experts in the field, who are motivators for young upcoming specialists, but also young scientists and students working in this fascinating field as well as the partners of the pharmaceutical industry, who are active in HS.

Participants of the 11th EHSF Conference will have the opportunity to share their knowledge and perspectives and to gain a better insight in HS. We have no doubt that your second virtual journey to Europe will be another interesting experience and we will make our best efforts to fulfill your scientific expectations and networking wishes.

On behalf of the EHSF e.V.
Prof. Dr. med. Prof. honoraire Dr. h.c. Christos C. Zouboulis, Dessau
ABOUT EHSF

OUR HISTORY

Founding of HSF, Inc.

In 2005, Mrs. Michele Barlow, a patient from San Diego, CA, USA, organized first funding to initiate the Hidradenitis Suppurativa Foundation, Inc. (HSF, Inc.), a tax-deducted organization according to the US law. In addition to Mrs. Barlow as president and co-founder, the first board of HSF Inc. included Mr. Robert Hoves, San Diego, CA, USA, vice president and co-founder, Prof. Dr. Ralf Paus, Luebeck, Germany, director of basic research and co-founder, Prof. Dr. Christos C. Zouboulis, Dessau, Germany, director of clinical research and co-founder, Mrs. Christine E. Pasela, San Diego, CA, USA, Mrs. Sylvia Shawcross, Chelsea, Quebec, Canada, Mrs. Mary Veta, San Diego, CA, USA, and Mrs. Lynn Edward Wiedell, San Diego, CA, USA. Experimental Dermatology became the official scientific journal of the HSF, Inc.

1st INTERNATIONAL HIDRADENITIS SUPPURATIVA RESEARCH SYMPOSIUM

The 1st International Hidradenitis Suppurativa Research Symposium took place on 30.03 – 02.04.2006 in Dessau, Germany. The milestones of the Symposium were the so-called Dessauer definition of the disease and the HSF 2006 Outstanding Investigator Award presented to Prof. Gregor B. E. Jemec. The attendees of this legendary meeting were Dr. David R. Adams, USA; Dr. Andreas Altenburg, Germany; Mrs. Michelle Barlow, USA; Dr. Martina Brunner, Germany; Dr. George Cotsarelis, USA; Dr. William Danby, USA; Dr. Alain Dupuy, France; Dr. Sabine Fimmel, Germany; Dr. Wolfgang Hartschuh, Germany; Dr. Dolores Herreros, Spain; Dr. Dorothee Hochheim, Germany; Mr. Robert Hoves, USA; Dr. Peter Hull, Canada; Dr. Gregor Jemec, Denmark; Dr. Yvonne Kroening, Germany; Dr. Ichiro Kurokawa, Japan; Dr. Hjalmar Kurzen, Germany; Dr. Evgenia Makrantonaki, Germany; Dr. Anirban Mandal, UK; Dr. Lynette Margesson, USA; Dr. Wolfgang, C. Marsch, Germany; Dr. W.H. Irwin McLean, Scotland; Dr. Samuel L. Moschella, USA; Dr. Ralf Paus, Germany; Dr. Uppala Radhakrishna, USA; Dr. Jean Revuz, France; Dr. Jihai Shi, Germany; Dr. Rodney Sinclair, Australia; Dr. John Sundberg, USA; Dr. Gilles Tachon, France; Dr. Antje Thielitz, Germany; Dr. Athanasios Theodoridis, Germany; Dr. Frangiski Tsatsou, Germany; Dr. Jan von der Werth, UK; and Dr. Christos C. Zouboulis, Germany.

LAST HSF, INC. BOARD WITH EUROPEAN PARTICIPATION

On 15.02.2012 a new HSF, Inc. board was elected (and re-elected on 11.02.2018) with Prof. Dr. Christos C. Zouboulis, Dessau, Germany, President and responsible for hidradenitis suppurativa/acro inversa guidelines, Prof. Gregor B.E. Jemec, Copenhagen, Denmark, vice president and responsible for clinical research, Prof. Dr. Ralf Paus, Luebeck, Germany/ Manchester, UK, vice president and responsible for experimental research, Mrs. Michelle Barlow, San Diego, CA, USA (former president, ex officio), treasurer and responsible for the Foundation, Prof. Richard Gallo, San Diego, CA, USA, Dr. Ichiro Kurokawa, Nishinomiya, Japan, Dr. George Varigos, Melbourne, Australia, Dr. Jan Lapins, Stockholm, Sweden, Dr. Paul Hazen, Westlake, OH, USA, responsible for patients’ communication and for the HSF Inc. website, Thomas Winkelk, Germany, patients’ representative, president Deutsche Interessengemeinschaft Akne inversa e.V., and Dr. Hessel H. van der See, Rotterdam, The Netherlands.

Despite the excellent and close cooperation among the involved scientists, the European Board members have recognized that bureaucratic issues in the USA made it more and more difficult for non-US citizens to run efficiently a US association. Therefore, Prof. Zouboulis resigned as HSF, Inc. president and member of the board on 27.02.2013 followed by Prof. Paus, leaving the leadership of the HSF, Inc. to US colleagues with Dr. Paul Hazen as new HSF, Inc. president from 02.03.2013. During its first meeting on 24.03.2014 the new HSF, Inc. board has granted Mrs. Michelle Barlow, Prof. Christos C. Zouboulis and Prof. Ralf Paus the honorary Founders HSF, Inc. membership.

INAUGURATION OF EHSF e.V.

The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) has been inaugurated on 29.09.2012 in Prague, Czech Republic as independent, sister society of HSF, Inc. The EHSF e.V. has been registered and recognized as a non-profit, public benefit organization (gemeinnütziger e.V.) according to the German law. General assemblies, take place annually during the annual International Conference of the Society.

FOUNDING MEMBERS

- Dr. Jurr Boer, Deventer/The Netherlands
- Prof. Dr. Veronique del Marmol, Brussels/Belgium
- Dr. Nemesha Desai, London/United Kingdom
- Dr. Deirdre Nathalie Dufour, Kalundborg/Denmark
- Dr. Lennart Emtestam, Stockholm/Sweden
- Prof. Dr. Gregor B.E. Jemec, Roskilde/Denmark
- Dr. Łukasz Matusiak, Wrocław/Poland
- Prof. Dr. Thrasivoulos Tzellos, Harstad, Troms/Norway
- Thomas Winkler, Lüdinghausen/Germany
- Dr. Hessel H. van der Zee, Rotterdam/The Netherlands
- Prof. Dr. Christos C. Zouboulis, Dessau-Rosslau/Germany
CONGRESSES

The 2nd International Hidradenitis Suppurativa Research Symposium took place on 05.03.2009 in San Francisco, IL, USA.

The 3rd International Hidradenitis Suppurativa Research Symposium (first of the EHSF e.V.) took place on 27.–28.02.2014 in Brussels, Belgium.

The 4th International Hidradenitis Suppurativa Research Symposium took place on 19.–20.02.2015 in Brussels, Belgium.

The 5th International Hidradenitis Suppurativa Conference, which was for the first time also open for non-members of the Society, took place on 10.–12.02.2016 in Berlin, Germany with 192 participants and 76 scientific contributions.

The 6th International Hidradenitis Suppurativa Conference took place on 8.–10.02.2017 in Copenhagen, Denmark with 202 participants and 77 scientific contributions.

The 7th International Hidradenitis Suppurativa Conference took place on 10.–12.02.2018 in Rotterdam, The Netherlands with more than 250 participants and 82 scientific contributions.

The 8th International Hidradenitis Suppurativa Conference took place on 10.–12.02.2019 in Wroclaw, Poland with 406 participants and 119 scientific contributions.

The 9th International Hidradenitis Suppurativa Conference took place on 5.–7.02.2020 in Athens, Greece. 422 participants from 48 countries with 137 scientific contributions participated at the conference.

The 10th International Hidradenitis Suppurativa Conference took place – due to the COVID-19 pandemic – at a digital mode – 10.–12.02.2021. 138 scientific contributions were presented and 688 participants from 52 countries took part.


OUR GOALS

- The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) pursues exclusively and directly charitable purposes within the meaning of the “tax-privileged purposes” of the tax code. Goal of the association is the promotion of science and research in field of the disease hidradenitis suppurativa/acne inversa.
- The goal of the association is raising funds for the promotion of research projects in the field of the disease hidradenitis suppurativa/acne inversa also to be achieved by support from other tax-exempt entities, public corporations or foreign entities whose activity is in line with the German Charity Law.
- Goal of the association is also the training of physicians, patients and laypersons.
- These goals are to be achieved
  - through lectures of educational character and
  - through public relations. Goal of the association is also raising funds for the promotion of public health care in the field of the disease hidradenitis suppurativa/acne inversa also from other tax-exempt entities, public corporations or foreign corporations whose activities are in line with the German non-profit law.
The Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; the Department of Dermatology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark; the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany; and the Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands are health care providers of the European Reference Network of Rare and Complex Skin Diseases (ERN Skin)

**SCIENTIFIC COMMITTEE**

Afşaneh Alavi (Rochester)
Daifallah Almansouri (Dessau)
Matthias Augustin (Hamburg)
Edileia Bagatin (Sao Paulo)
Falk Bechra (Bochum)
Pierre-André Becherel (Paris)
Farida Benhadou (Brussels)
Vincenzo Bettoli (Ferrara)
Yousef Binamer (Riyadh)
Jurr Boer (Deventer)
Raffaele D. Caposiena Caro (Rome)
Nisha S. Chandran (Singapore)
Aron D. Cohen (Has Hasharon)
Veronique del Marmol (Brussels)
Maïa Delage-Toriel (Paris)
Alireza Firooz (Tehran)
John W. Frew (Sydney)
Ruta Ganceviciene (Vilnius)
Simone Garcovich (Rome)
Evangelos J. Giamarellos-Bourboulis (Athens)
Katalin Glasenhardt (Szeged)
Matthias Goebeler (Wuerzburg)
Philippe Guillemin (Écully)
Wayne Gulliver (St. John’s)
Ariela Hafner (Tel Aviv)
Iltefat Hamzavi (Detroit)
Yuval Hilerowicz (Tel Aviv)
Barbara Hórvath (Croningen)
Evgenia Hristakieva (Stara Zagora)
Robert E. Hunger (Bern)
John R. Ingram (Cardiff)
Gregor B.E. Jemec (Roskilde)
Olivier Join-Lambert (Caen)
Alexander Katoulis (Athens)
Lajos Kemény (Szeged)
Alexa B. Kimball (Boston)
Brian Kirby (Dublin)
Joslyn S. Kirby (Hershey)
Nathalie Kirsten (Hamburg)
Maria P. Konstantinou (Toulouse)
Athanasios Kyrgidis (Thessaloniki)
Michelle Lowes (New York)
Antonio Martorell (Manises)
Angelo V. Marzano (Milan)
Łukasz Matusiak (Wroclaw)
Dillon Mintoff (Valetta)
Alejandro Molina-Leyva (Granada)
Haley Naik (San Francisco)
Aude Nassif (Paris)
Georgios Nikolakis (Dessau)
Hazel H. Don (Singapore)
Andreas Pinter (Frankfurt/M.)
Maurizio Podda (Darmstadt)
Errol P. Prens (Rotterdam)
Francesca Prignano (Florence)
Luis Puig (Barcelona)
Jorge Romani (Barcelona)
Marco Romanelli (Pisa)

**EHSF ORGANIZING COMMITTEE**

Gregor B.E. Jemec (Roskilde, Denmark)
Veronique Del Marmol (Brussels, Belgium)
Angelo V. Marzano (Milan, Italy)
Errol P. Prens (Rotterdam, The Netherlands)
Thrasyvoulos Tzellos (Bode, Norway)
Christos C. Zouboulis (Dessau, Germany)
LOCAL ORGANIZING COMMITTEE

Christos C. Zouboulis
Georgios Nikolakis
Daifallah Almansouri
Hendrik Hansen
Amir M. Hossini
Anna Kristandt
Henriette von Waldthausen
Viktor A. Zouboulis

OVERALL LEARNING OBJECTIVES

To present innovative basic and clinical research on hidradenitis suppurativa
To discuss and exchange opinions on new hidradenitis suppurativa treatment developments in an international setting
To address hidradenitis suppurativa unmet needs and future collaborative projects

PRIZES

Poster prizes raised by the EHSF e.V. (1st prize 1000 €, 2nd prize 600 €, 3rd prize 400 €)
Young investigators prizes raised by the ERN Skin-ALLOCATE Skin group (5 prizes of 200 € for active participants under 30 year-old - lectures/poster presenters - who have to apply for the prize with CV, including date of birth and abstract submission)

PRIZE COMMITTEE:
D. Almansouri
R. Ganceviciene (chair)
S. Garcovich
A. Katoulis
N. Kirsten
M.P. Konstantinou
A. Kyrgidis
F. Tsatsou
Patient Association Representatives Chat Room

Coordination:
- Farida Benhadou (Brussels)
- Katalin Glasenhardt (Szeged)
- Linnea Thorlacius (Roskilde)

Participants (until 01.02.2022):
- Association Française pour la Recherche sur l’Hidrosadénite
- Dutch HS Patient Organisation
- HS International Sweden
- Irish HS Patients Organization
- Norwegian HS Patients Organization

Participants (invited):
- Belgian HS Patients Association
- Deutsche Akne Inversa Patientenvereinigung
- HS Connect USA
- mullewupp Akne inversa Selbsthilfe e.V.
- Patientforeningen HS Danmark
THURSDAY PROGRAM OVERVIEW

08.00–09.00 (CET) EHSF e.V. General Assembly
(Members only)

09.50–10.00 (CET) Welcome Address

10.00–12.15 (CET) Scientific Session 1 – Epidemiology, Syndromes and Diagnostic Tools (Clinical Phenotypes, Outcome Measures)

12.15–12.45 (CET) 1st Invited Lecture – Molecular analysis of inflammatory diseases


13.45–15.00 (CET) Poster Session

15.00–17.45 (CET) Scientific Session 2 – Basic and Translational Research (Genetics, Immunology, Biomarkers, Phenotypes)

17.45–18.30 (CET) Poster Session

11th EHSF Conference Abstract Book
Poster Viewing
Clinical characterization of paediatric-onset hidradenitis suppurativa: results from a multicenter European study
Francesca Prignano (Florence)

Hidradenitis suppurativa in patients with pilonidal sinus disease: development and internal validation of a risk calculator
Philippe Guillem (Écully)

Prevalence of inflammatory bowel diseases in hidradenitis suppurativa/ acne inversa population – results from the German Hidradenitis-Suppurativa-Registry HS-BEST
Nathalie Kirsten (Hamburg)

The overlapping pathogenesis of Crohn’s disease and hidradenitis suppurativa explored
Camilla Frederiksen (Roskilde)

The differentiating effect of COVID-19-associated stress on the morbidity of healthy blood donors with symptoms of hidradenitis suppurativa
Matthias A. Henning (Roskilde)

Dietary intake and physical activity of hidradenitis suppurativa patients in a large population-based cohort
Klasiena Bouwman (Groningen)

Outcome measures for moderate and severe hidradenitis suppurativa: lessons learned from the SHINE study
Evangelos J. Giamarellos-Bourboulis (Athens)

Clinical practice trends in the procedural management of hidradenitis suppurativa (HS) in the UNITE HS Registry
Manila Oliveira (North Chicago)

Hidradenitis suppurativa international online community: Patient characteristics and a novel model of treatment effectiveness
Shany Sherman (Petah Tikva)

Development of novel precision medicine tools for the diagnosis and treatment of hidradenitis suppurativa by the BATMAN consortium
Sergio Crovella (Doha/Milan)

Use of artificial intelligence pattern recognition for the diagnosis and staging of hidradenitis suppurativa
Dimitri L. F. Silva (Campinas)

Development and validation of an IHS4 dichotomous outcome to assess treatment effect
Kelsey R. Van Straalen (Rotterdam)

Discussion

12.15–12.45 1st Invited Lecture – Molecular analysis of inflammatory diseases
Sergio Crovella (Doha/Milan)

Chairs:
Angelo V. Marzano (Milan)
Barbara Hórvath (Groningen)

The EHSF widens its cooperative research activities and it is important for its members and beyond to learn which are the upcoming “big projects”.
In this session, the speakers will report on the new scientific projects of EHSF and will communicate the current status and procedures in the development of hidradenitis suppurativa projects and how they can support innovation in hidradenitis suppurativa
Chairs:
John R. Ingram (Cardiff)
Wayne Gulliver (St. John’s)
Errol P. Prens (Rotterdam)
Thrasyvoulos Tzellos (Bodø)
**European Registry for Hidradenitis Suppurativa (ERHS): Presentation of the data collected since 2015**
Stephanie Heudens (Brussels)

**Hidradenitis suppurativa phenotypes: Validation attempt of a multidimensional latent class analysis of the National Italian Registry (IRHIS)**
Vincenzo Bettoli (Ferrara)

**Application of insurance data**
Matthias Augustin (Hamburg)

**HORUS and GHISA**
Gregor B.E. Jemec (Roskilde)

**The EHSF GWAS approach**
Errol P. Prens (Rotterdam)

**The EHSF GWAS Study: An Invitation to participate**
Christos C. Zouboulis (Dessau)

**Distribution of monogenic etiologies in a racially diverse hidradenitis suppurativa (HS) cohort**
Lynn Petukhova (New York)

**Genetic architecture of hidradenitis suppurativa revealed by a genome-wide association study**
Evangelos J. Giamarellos-Bourboulis (Athens)

**Single-cell transcriptomic profiling of hyperproliferative keratinocytes in hidradenitis suppurativa**
Conor M. Smith (Dublin)

**Primary alterations in the development of hidradenitis Suppurativa**
Krisztian Gaspar (Debrecen)

**Progressor Inflammatory hidradenitis suppurativa phenotype: A genotype-phenotype correlation based on a prospective epigenomic analyses**
Antonio Martorell (Manises)

**B cell and complement signature in severe hidradenitis suppurativa which does not respond to adalimumab**
Roisin Hambly (Dublin)

**The effect of metformin on cardiovascular disease biomarkers in hidradenitis suppurativa**
Roisin Hambly (Dublin)

**Anti-inflammatory effect of metformin on peripheral mononuclear cells of patients with moderate to severe hidradenitis suppurativa**
Evangelos J. Giamarellos-Bourboulis (Athens)

**Down-expression of CXCL16/CXCR6 by hypermethylation involved in pathogenesis of in acne inversa/hidradenitis suppurativa**
Zhongshuai Wang (Beijing)

**Disease association of anti-CEL autoantibodies in hidradenitis suppurativa**
Ben Roediger (Basel)
Systemic immune-inflammation index is a biomarker of systemic inflammatory burden and cardiovascular co-morbidities in hidradenitis suppurativa and psoriasis
Niamh Kearney (Dublin)

Transient elastography for assessment of sinus tracts fibrosis in hidradenitis suppurativa
Eva Vilarrasa (Barcelona)

Anti-inflammatory effects of rifampicin in an ex vivo culture model of hidradenitis suppurativa
Isabel Haferland (Frankfurt am Main)

The anti-inflammatory effect of adalimumab assessed using the hidradenitis suppurativa 3D-SeboSkin model
Xiao X. Hou (Dessau)

Discussion
## FRIDAY PROGRAM OVERVIEW

**Friday, February 11, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00–09.00</td>
<td>Poster Session</td>
</tr>
<tr>
<td>09.00–10.30</td>
<td>Scientific Session 3 – Hidradenitis suppurativa around the World</td>
</tr>
<tr>
<td></td>
<td>(Selected International Contributions)</td>
</tr>
<tr>
<td>10.30–12.30</td>
<td>Scientific Session 4 – Treatment Innovations A (Local Treatments,</td>
</tr>
<tr>
<td></td>
<td>Systemic Treatments, Surgical Treatments)</td>
</tr>
<tr>
<td>12.30–13.00</td>
<td>2nd Invited Lecture – New immunological tools for understanding</td>
</tr>
<tr>
<td></td>
<td>inflammatory diseases</td>
</tr>
<tr>
<td></td>
<td>11th EHSF Conference Abstract Book</td>
</tr>
<tr>
<td>13.00–15.00</td>
<td>Scientific Symposium 2 – Innovations Part I (New Treatments, new</td>
</tr>
<tr>
<td></td>
<td>Assessment instruments)</td>
</tr>
<tr>
<td></td>
<td>Part II (Comorbidities of hidradenitis suppurativa: Implications for</td>
</tr>
<tr>
<td></td>
<td>daily clinical practice)</td>
</tr>
<tr>
<td>15.00–17.00</td>
<td>Scientific Session 5 – Treatment Innovations B (Clinical Trials,</td>
</tr>
<tr>
<td></td>
<td>Imaging)</td>
</tr>
<tr>
<td>17.00–18.00</td>
<td>Selected Poster Session – Poster Prizes</td>
</tr>
<tr>
<td>18.00–18.15</td>
<td>Conference Closing/Announcements</td>
</tr>
<tr>
<td></td>
<td>11th EHSF Conference Abstract Book</td>
</tr>
<tr>
<td></td>
<td>Poster Viewing</td>
</tr>
</tbody>
</table>

---

### Scientific Session 3 – Hidradenitis suppurativa around the World (Selected International Contributions)

Main learning objectives of this session are:
- to communicate specific issues on hidradenitis suppurativa epidemiology, clinical picture and treatment in different populations and geographic areas of the world
- to exchange the knowledge development and built up and corroborate international cooperations

**Chairs:**
- Lajos Kemény (Szeged)
- Ditte M. Saunte (Roskilde)
- Skaidra Valiukeviciene (Kounas)

**Hidradenitis suppurativa in**
- USA - Iltefat H. Hamzavi (Detroit)
- East South America - Edileia Bagatin (Sao Paulo)
- West South America - Ximena Wortsman (Santiago)
- Arabic countries - Yousef Binamer (Riyadh)
- Middle East - Alireza Firooz (Tehran)
- China - Baoxi Wang (Peking)
- Korea - Dae H. Suh (Seoul)
- South East Asia - Hazel H. Don (Singapore)
- Australia - John W. Frew (Sydney)
Scientific Session 4a – Treatment Innovations A (Local Treatments, Systemic Treatments, Surgical Treatments)

Main learning objectives of this session are:
- to summarize the new evidence on local, systemic and surgical treatments,
- their implications in daily clinical practice and
- how they can shape current treatment strategies and promote better combination of medical and surgical approaches.

Chairs:
Falk Bechara (Bochum),
Philippe Guillem (Écully),
Brian Kirby (Dublin)
Marco Romanelli (Pisa)

Dapsone in hidradenitis suppurativa: why, who, when, and how
Jorge Romani (Barcelona)

Pediatric population in the Institut Pasteur Hidradenitis Suppurativa patient group: characteristics and evolution after antibiotic treatment
Maia Delage-Toriel (Paris)

Drug survival of adalimumab biosimilar and Adalimumab originator in patients with hidradenitis suppurativa: A retrospective single centre cohort of 80 patients
Fernando Alfageme (Madrid)

Adalimumab accelerates chronic cutaneous wound healing in vivo by inducing a distinct healing signature
Yonghao Cao (Worcester)

Profile of patients operated for hidradenitis suppurativa in France in 2021
Anne C. Ezanno (St Mandé)

Post-surgical patient reported outcomes after deroofing and secondary intention healing: a prospective series of 53 cases
Antonio Martorell (Manises)

Validity and reliability of two digital wound measurement apps after surgery in patients with hidradenitis suppurativa
Pin Aarts (Rotterdam)

Surgery in hidradenitis suppurativa through the prism of published guidelines
Philippe Guillem (Écully)

Utilizing the ACS-NSQIP database to identify the characteristics and outcomes of patients receiving surgery for hidradenitis suppurativa
Dany Y. Motor (Boston)

Evolution of clinical practice in the medical management of hidradenitis suppurativa (HS) in the UNITE HS Registry
Alexa B. Kimball (Boston)

Therapeutic approach algorithm from the hidradenitis suppurativa workgroup of the Chilean Society of Dermatology and Venereology
Francisco Reyes-Baraona (Santiago)

Discussion
**Scientific Symposium 2 - Innovations**

Chairs: Gregor B.E. Jemec (Roskilde), Francesca Prignano (Florence), Jacek C. Szepietowski (Wroclaw), Christos C. Zouboulis (Dessau)

**Part I. New Treatments, New Assessment Instruments:**
Trials of new treatments inevitably require clinimetric assessment. The development of new treatments in hidradenitis suppurativa is in the desirable position of taking place in an open field putting an emphasis on collaboration opportunities and an evidence-based assessment providing a stable foundation for balanced recommendations.

In this session, the speakers are going to discuss the clinimetric options available for trials of new treatments.

- **Investigator assessed outcomes**
  Kelsey R. Van Straalen (Rotterdam /Ann Arbor)

- **Patient assessed outcomes**
  John R. Ingram (Cardiff)

- **How to make patient assessed outcomes objective**
  Christos C. Zouboulis (Dessau)

- **Real world data as outcomes**
  Matthias Augustin (Hamburg)

**Discussion**

**Part II. Comorbidities of hidradenitis suppurativa:**
Implications for daily clinical practice:
Inflammatory diseases have been treated according to evidenced-based studies and the subsequent registration of drugs. Current research, however, indicates the contribution of emerging comorbid disorders in treatment outcomes. In this session, the speaker is going to discuss how comorbid disorders influence the real world treatment of hidradenitis suppurativa now and in the future.

---

**Scientific Session 5 – Treatment Innovations B**

Main learning objectives of this session are
- To provide an overview of the current pipeline (phase 2 and 3 studies)
- To discuss how imaging could facilitate rational treatment decision making

Chairs: Antonio Martorell (Manises), Łukasz Matusiak (Wroclaw), Maurizio Podda (Darmstadt), Luis Puig (Barcelona)

**Evaluation of resorcinol 10% in the treatment of hidradenitis suppurativa Hurley I stage: a randomized prospective open study**
Georgia Pappa (Athens)

**LAight® therapy can maintain long-term remission of Hurley I and II hidradenitis suppurativa: Results from period B of RELIEVE, a multicenter randomized, controlled trial**
Georgios Nikolakis (Dessau)

**Efficacy of subantimicrobial, modified-release doxycycline compared to regular-release doxycycline for the treatment of hidradenitis suppurativa**
Georgios Kontochristopoulos (Athens)

**Short-term i.v. clindamycin accelerates the benefit of oral clindamycin-rifampicin treatment in hidradenitis suppurativa (HS)**
Anna Kristandt (Dessau)
Rapid reduction of inflammation in severe hidradenitis suppurativa following treatment with the PDE4-inhibitor Orismilast
Elisabeth H. Taudorf (Roskilde)

Treatment of severe hidradenitis suppurativa and atopic dermatitis with combined anti-TNF and IL-4/13 antagonist
Yousef Binamer (Riyadh)

Guselkumab for hidradenitis suppurativa: a phase II open label, mode of action study
Koen Dudink (Rotterdam)

Impact of surgery in hidradenitis suppurativa: results of a prospective French multicenter study
Anne C. Ezanno (St Mandé)

Railway line' sign, a new ultrasound feature that predicts a surgical approach in dermoepidermal tunnels
Antonio Martorell (Manises)

Discussion

17.00-18.00
Selected Poster Session – Poster Prizes
Evaluation Committee:
Daifallah Almansouri (Dessau)
Ruta Ganceviciene (Vilnius), chair
Simone Garcovich (Rome)
Alexander Katoulis (Athens)
Nathalie Kirsten (Hamburg)
Maria P. Konstantinou (Toulouse)
Antonios Kyrgidis (Thessaloniki)

18.00-18.15
Conference Closing/ Announcements
Gregor B.E. Jemec (Roskilde)
Christos C. Zouboulis (Dessau)

1. EPIDEMIOLOGY AND DIAGNOSTIC TOOLS

Hidradenitis suppurativa: experience of a center in Sao Paulo, Brazil
M.C. Rivitti-Machado, T.B. Macedo, P. Geiera

Epidemiology of hidradenitis suppurativa in a dermatology single - center study in the city of Santos, State of Sao Paulo, from 2018 to 2021

Hidradenitis suppurativa prevalence in Nuuk, Greenland – initial validation of a hidradenitis suppurativa questionnaire in a Greenlandic setting

Sociodemographic, clinical, treatment characteristics and natural course of hidradenitis suppurativa: a single center case series of 100 patients
K. Mamadi, A. Bilgiç, E. Alpsoy

Biopsychosocial factors associated with quality of life in patients with hidradenitis suppurativa: results from the global VOICE project
J. Koptev, S. Rawal, A. Shetty, A. Strunk, A. Carg

Identification of phenotypic features of paediatric-onset hidradenitis suppurativa associated to diagnostic delay: results from a multicenter observational study

Hidradenitis Suppurativa – a collaborative study of subtypes – HORUS
2. CLINICAL SIGNS, SYNDROMES, COMORBIDITIES

- Clinical factors associated with intima media thickness in patients with moderate to severe hidradenitis suppurativa

- Under-recognized knife-like lesions in advanced hidradenitis suppurativa

- Follicular occlusion syndrome in the population of Russian patients with moderate to severe hidradenitis suppurativa
  A.S. Pirogova, N.P. Teplyuk

- External validation of the Hidradenitis Suppurativa Cutaneous Abscess Prediction Score-1 (HSCAPS-1): a prediction model for diagnosis of hidradenitis suppurativa over site-specific cutaneous abscess
  A. Garg, J. Koptevy, A. Strunk, M. Butt, J. Kirby

- The co-occurrence of keratosis pilaris and hidradenitis suppurativa: results from a monocentric retrospective study
  A. Di Cesare, E. Magnaterra, F. Montefusco, E. Rosi, F. Prignano

- Under-recognized knife-like lesions in advanced hidradenitis suppurativa

- Follicular occlusion syndrome in the population of Russian patients with moderate to severe hidradenitis suppurativa
  A.S. Pirogova, N.P. Teplyuk

- The co-occurrence of keratosis pilaris and hidradenitis suppurativa: results from a monocentric retrospective study
  A. Di Cesare, E. Magnaterra, F. Montefusco, E. Rosi, F. Prignano

- Worsened signs in patients with hidradenitis suppurativa treated at a dermatology referral center in Chile
  F. Reyes-Baraona, M.J. Lorenzoni

- Gluteal hidradenitis suppurativa: analysis of 83 patients

- Anogenital involvement: clinical sign of severity in hidradenitis suppurativa

- Depression and anxiety among hidradenitis suppurativa patients
  J. E. Rymaszewska, P. Krajewski, J.C. Szepietowski

- The psychosocial impact and treatment trends of hidradenitis suppurativa in Singapore

- Severe and fatal complications of the anogenital phenotype of hidradenitis suppurativa

- Cancer risk in patients with hidradenitis suppurativa
  C. Ciudad Blanco, O. Baniandres Rodriguez, R. Suárez Fernández
p-029 Comorbidities associated with relapse after surgical treatment for hidradenitis suppurativa
M.C. Loureiro, V.P. Sousa, F.D. Rio, A.L.A. Silva, C.B. Barcoui, S. Coelho

p-077 A case report of Budd-Chiari syndrome associated with severe hidradenitis suppurativa
Y. Binamer

p-064 Low incidence of COVID-19 in hidradenitis suppurativa: how to interpret it?
M. Dewigne, C. Orte Cano, M. Daoud, V. del Marmol, F. Benhadou

p-129 Incidence of COVID-19 hospitalization in patients with hidradenitis suppurativa
J. Koptyev, A. Strunk, A. Garg

p-068 Impact of COVID-19 pandemic on hidradenitis suppurativa patients
B. Horváth, K. Bouwman

p-161 May COVID-19 infection induce a paradoxical improvement of a non-responsive case of hidradenitis suppurativa?
R.D. Caposiena Caro, C. Pensia, S. Lambiase, E. Candi, L. Bianchi

p-090 Quality of life assessment in patients suffering from hidradenitis suppurativa with the use of newly developed HSQoL-24

p-062 The Hidradenitis suppurativa journey: a survey of US patients and providers
J.S. Kirby, J.L. Hsiao, E. Muscianisi, E. Nguyen, V.V. Shi

p-069 The proportion of self-diagnosed hidradenitis suppurativa in patients with spondyloarthritis, based on the online MyHealthTeams survey
A. Spoorenberg, H. Lapidus Classner, I. Pansar, M. Kim, B. Horváth

3. EDUCATION, BASIC AND TRANSLATIONAL RESEARCH

p-050 Relevance of education on hidradenitis suppurativa: a single centre experience
E. Rosi, I. Scandagl, M.T. Fastame, G. Silvi, A. Di Cesare, F. Prignano

p-115 Sustainable patient education in hidradenitis suppurativa
E.M.M. Christensen, S. Esmann, D.M.L. Saunte, G. Jemec

p-178 Global Hidradenitis Suppurativa Atlas – GHISA

p-153 Intrafamily concealning for hidradenitis suppurativa: what can we learn from intrafamily variability?
V. Vlaeminck-Guillen, P. Guilm

p-156 Hidradenitis suppurativa-related expenditure, a call for awareness: systematic review of literature
A. Tsentemeidou, E. Sotiriou, E. Vakirlis, D. Ioannides

4. THERAPEUTIC PROCEDURES

p-041 The mechanical stress in skin folds as an explanation of the location of hidradenitis suppurativa lesions
T. Saad, C. Niordson, J. Boer, G.B.E. Jemec

p-135 A novel NCSTN mutation is associated with Dowling-Degos disease and hidradenitis suppurativa in a 4-generation Brazilian family
A.S. Lima Estevao de Oliveira, R. Cardosa de Siqueira, C. Nair-Medda, P.M. Tricarico, S. Jomain, S. Croella, L. Branão, M. Baniotto

p-148 Hidradenitis suppurativa and comorbid disorder biomarkers - A molecular meta-analysis
V.A. Zouboulis, K.C. Zouboulis, C.C. Zouboulis

p-167 Resorcinol peel as a treatment of painful nodules in hidradenitis suppurativa: Report of 4 cases
M.T. Molina, D. Carvajal

p-165 Doxycycline 40 mg long release in the treatment of mild hidradenitis suppurativa: a case series
M.V. Cannizzaro, C. Pensia, S. Lambiase, V. Maffei, R. Gaeta Shumak, E. Batti, L. Bianchi

p-151 Moxifloxacin-metronidazole combination without rifampicin for the treatment of hidradenitis suppurativa: experience in a tuberculosis-endemic country
F. Reyes-Baroando, I. Garcia-Huidobro, M.J. Lorenzoni

p-169 Acitretin as adjuvant therapy in the treatment of refractory hidradenitis suppurativa
N.P. Cosgrave, G. O’Connell, S. O'Mahoney, E. Keeling, A.-M. Tobin

p-094 Drug survival of hidradenitis suppurativa patients treated with retinoids
K. Bouwman, P. Aarts, K. Dudink, J. Hao, B. Alizadeh, H.H. van der Zee, B. Horváth

p-056 Adalimumab long-term treatment in hidradenitis suppurativa patients
E. Rosi, A. Di Cesare, M.T. Fastame, I. Scandagl, G. Silvi, F. Prignano

p-096 Successful treatment with high dosage infliximab after failure of IL17 inhibitors: a series of 12 hidradenitis suppurativa’s patients
A.-C. Fougerousse, P.-M. Becherel

p-065 Biosimilar effectiveness in hidradenitis suppurativa patients previously treated with reference adalimumab
A. Trigoni, E. Mingioni, T. Tsatsou, P. Melzandou, E. Lazoridou

p-011 Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-IL17 failures
R.D. Caposiena Caro, C. Pensia, S. Lambiase, E. Candi, L. Bianchi
p-152 Hidradenitis suppurativa: Biologic therapy and the need for additional therapies
R.R. Matos, G. Rosa, A. Cerejeira, M.J. Cruz, S. Magina, F. Azevedo, C. Lisboa

p-172 TNF-induced paradoxical psoriasis in hidradenitis suppurativa

p-106 Paradoxical psoriasis developed in 8 hidradenitis suppurativa patients treated with adalimumab
A. Liakou, E. Agiasofitou, A. Tsiooka, K. Bonatsou, M. Papadakis, M. Papazisi, S. Vladeni, A. Katoulis, A. Stratigos, D. Rigopoulos, G. Kontochristopoulos

p-145 Sorafenib-induced hidradenitis suppurativa: A case report

p-171 Sunitinib–induced hidradenitis suppurativa in a patient with metastatic renal cell carcinoma: mechanistic insights

p-142 Proposed thickness cut-offs for inflammatory induration grading for the hidradenitis suppurativa activity and severity index revised (HASI-R)
G. Bellefeuille, B. Palevovksy, B. Khalid, R.L. Freese, M.A. Lowes, J.S. Kirby, A. Alavi, N. Goldfarb

p-144 Dermasurgery by acne inversa - Better outcome with ALTRAZAL™? 
N. Ben Anaya, M. Augustin, F. Ohm, C. Girbig, N. Kirsten

p-020 Evaluation of the effectiveness and benefits of the CO2 laser excision technique in surgical cases of hidradenitis suppurativa

p-019 Atypical ductal mammary hyperplasia: An incidental histopathological finding in a surgical piece of axillary hidradenitis suppurativa
D. Peirano Deck, C. Hastijn Zegpl, D. Saavedra Ruiz

p-058 Risk factors implicated in surgical recurrence in patients with hidradenitis suppurativa

p-025 Potential benefits of the Mediterranean diet and physical activity in patients with hidradenitis suppurativa: a cross-sectional study in a Spanish population

5. CLINICAL STUDIES AND TREATMENT INNOVATIONS

p-123 Topical timolol as adjuvant treatment in hidradenitis suppurativa: report of 2 cases
I. García-Huidobro, F. Reyes-Barraona, M.J. Lorenzoni

p-086 OSIRIS – Orismilast for the treatment of mild to severe hidradenitis suppurativa: Rationale and design
E.H. Taudorf, G.B.E. Jemec

p-047 Impact of biologics on procedural interventions and healthcare utilization in the UNITE HS
M. Oliveira, K. Rahawi, Y. Duan, C. Sayed

p-166 Switching between biosimilars and originator in hidradenitis suppurativa: retrospective study on biosimilar failure after originator
M.V. Cannizzaro, V. Maffei, R. Gaeta Shumak, S. Lambiase, C. Penso, E. Batti, L. Bianchi

p-013 Guselkumab dosing and intervals in patients with moderate severe hidradenitis suppurativa. A retrospective single centre experience
F. Alfrageme, M. Hospital, I. Salgüero, G. Roustan

p-118 Refractory, severe hidradenitis suppurativa Hurley stage III shows positive response to a therapy with the combination of Brodalumab (IL-17-receptor inhibitor) and Upadacitinib (JAK-inhibitor). A case report
C. Gewiss, M. Augustin, N. Kirsten

p-155 Anti-IL-23 in hidradenitis suppurativa: unveiling a new pathway
E. Marques, M. Arenbergerová, A. Smaradová, P. Arenberger

p-06 Adjuvant therapy with laser and botulinumtoxin-A in hidradenitis suppurativa
R. Nienstedt, B. Rümmelein

p-149 New drugs and drug repurposing for hidradenitis suppurativa
C.C. Zouboulis, V.A. Zouboulis, K.C. Zouboulis

p-080 Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project
B. Midgette, A. Strunk, A. Carg
General Information

Scientific Organizer
European Hidradenitis Suppurativa Foundation e.V.
Auenweg 38, 06847 Dessau-Rosslau
www.ehsf.eu

Prof. Dr. Christos C. Zouboulis
President of the EHSF e.V.

Professional Congress Organizer
MCI Deutschland GmbH
Markgrafenstrasse 56
10117 Berlin
T: +49 30 20459230
F: +49 30 2045950

Contact
Project Management
Viktoria Solotar
T: +49 30 20459374
ehsf@mci-group.com

Sponsoring/Exhibition
Kristina Van Cleave
T: +49 30 20459469
ehsf-sponsoring@mci-group.com